-
Mashup Score: 32
Human epidermal receptor tyrosine kinase 2 (HER2/ERBB2) mutation is recognized as a critical driver of non-small cell lung cancer (NSCLC), occurring in approximately 2 %–3% of patients [1–3]. These patients typically experience poor prognosis, with a median overall survival (OS) of only 1.6–1.9 years from the diagnosis of metastatic disease[4], which is lower than that of patients without driver mutations. HER2-targeted therapies such as afatinib, dacomitinib, and neratinib have shown limited efficacy in improving outcomes compared to chemotherapy [5–7].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47
Lung cancer is the leading cause of cancer-related deaths globally, with small-cell lung cancer (SCLC) accounting for 15–20 % of all cases, the majority (two-thirds) of which are extensive-stage SCLC (ES-SCLC) cases [1,2]. The development of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) has significantly altered treatment strategies for ES-SCLC, improving patient outcomes [3–5]. In a pivotal phase 3 trial (the IMpower133 trial), patients with ES-SCLC who received atezolizumab in addition to chemotherapy demonstrated significantly higher progression-free survival (PFS) and overall survival (OS) than those receiving chemotherapy alone [6].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Real-world analysis of first-line carboplatin, etoposide, atezolizumab for extensive stage #SCLC with ≥3y f/u now @LungCaJournal. In 207 pts, the 3y OS rate was 21%. Need to build on this backbone, but long-term survival is possible for some. https://t.co/H5Keq6trWz
-
-
Mashup Score: 13
The RAS gene family consists of KRAS, HRAS, and NRAS, which encodes membrane-associated 21 kDa proteins with guanosine triphosphatase (GTPase) activity [1,2]. In the physiological state, when RAS receives an upstream signal from receptor tyrosine kinases (RTK), it is converted from a guanosine diphosphate (GDP)-bound inactive form to a GTP-bound active form, which activates several downstream signaling pathways involved in various physiological activities (Fig. 1) [1,2].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
RT @BertrandBio: The next-generation #KRAS inhibitors…What comes after sotorasib and adagrasib? https://t.co/6TtpeFCot9 https://t.co/UB3L…
-
-
Mashup Score: 45
In non-small cell lung cancer (NSCLC), BRAF V600E (V Raf murine sarcoma viral oncogene homolog) mutations account for 2–5 % of cases [1,2]. The BRAF gene (long arm of chromosome 7) encodes a serine/threonine kinase protein that regulates the signaling pathway RAS-RAF-MEK-ERK and plays an important role in proliferation, cell survival, angiogenesis, cell invasion and migration [4–7]. BRAF mutations can be divided into three different classes, which differ in terms of RAS dependency and the activity of each catalytic domain.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Real world outcomes with dabrafenib + trametinib in #BRAF V600E NSCLC @LungCaJournal (IFCT-2004 BLaDE, n=163). First-line: RR 83%, PFS 18m, OS 24m. Later line: RR 74%, PFS 10m, OS 20m. Discontinuation for toxicity ~10%. https://t.co/EpT6P1RYin
-
-
Mashup Score: 119
Osimertinib is a third generation EGFR tyrosine kinase inhibitor (TKI) for patients with metastatic EGFR mutant non-small cell lung cancer (NSCLC) [1–2]. Unfortunately, acquired resistance is inevitable and defining the optimal treatment strategies for patients who progress on osimertinib remains a clinical challenge. Different mechanisms of resistance to osimertinib have been well described [3–7], and adaptative therapies that target actionable mechanisms of resistance yield improved post-progression clinical outcomes [8–13].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Is there value in continuing osimertinib beyond progression? Retrospective analysis in @LungCaJournal showed longer PFS with continuing TKI - but this is still an open question that will be answered with the prospective COMPEL trial. https://t.co/8Jka1mz3Uu
-
-
Mashup Score: 17Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison - 1 month(s) ago
Globally, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death [1]. Over 2.2 million new cases were diagnosed in 2020 [2]. Lung cancer is often diagnosed in later stages, leading to its overall low survival rate [3]. The majority (approximately 80 %) of lung cancer cases are non-small cell lung cancer (NSCLC) [4]. NSCLC represents a heterogeneous group of lung cancers that harbors a variety of genetic mutations/alterations [5]. These mutations or alterations can be used to inform treatment decisions (i.e., molecular-guided treatment), particularly in patients with advanced or metastatic disease.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Matching-adjusted indirect comparison between entrectinib and crizotinib in Asian pts with #ROS1 NSCLC @LungCaJournal. Imperfect analysis but PFS favored entrectinib (39.4m vs 15.9m). https://t.co/CDOpPlY6EA
-
-
Mashup Score: 23Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison - 1 month(s) ago
Globally, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death [1]. Over 2.2 million new cases were diagnosed in 2020 [2]. Lung cancer is often diagnosed in later stages, leading to its overall low survival rate [3]. The majority (approximately 80 %) of lung cancer cases are non-small cell lung cancer (NSCLC) [4]. NSCLC represents a heterogeneous group of lung cancers that harbors a variety of genetic mutations/alterations [5]. These mutations or alterations can be used to inform treatment decisions (i.e., molecular-guided treatment), particularly in patients with advanced or metastatic disease.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Matching-adjusted indirect comparison between entrectinib and crizotinib in Asian pts with #ROS1 NSCLC @LungCaJournal. Imperfect analysis but PFS favored entrectinib (39.4m vs 15.9m) https://t.co/5sgiZWpoyO
-
-
Mashup Score: 29
Stage IIIA-N2 non-small cell lung cancer (NSCLC) is a highly heterogenous cancer with broad patient and disease characteristics in terms of the number and status of lymph node metastases [1,2]. For many years, radical surgery was the mainstay treatment approach if deemed feasible. In the last decade, it has become clear that patients with Stage IIIA-N2 NSCLC should be considered for multimodal therapies, including chemotherapy (CT), radiotherapy (RT), or chemoradiotherapy (CRT), which may be performed alone or in combination with surgery [3–14].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Real world outcomes in stage IIIA-N2 NSCLC from @HHorinouchi et al @LungCaJournal. 59% had chemoradiation, others had surgery +/- perioperative therapy. 3y OS rate 62% with surgery + periop, 42% with CRT, 38% with surgery alone. https://t.co/JZwl6c9BwN
-
-
Mashup Score: 110Oral propranolol for the treatment of amivantamab-induced scalp ulcers with granulation tissues - 2 month(s) ago
This 57-year-old man presented with a chronic cough with sputum and weight loss since October 2019. Subsequent computed tomography (CT) scans confirmed stage IV lung cancer without brain metastases. He underwent video-assisted thoracoscopic surgery for a right middle lobe wedge resection on December 20, 2019, and pathology confirmed adenocarcinoma, Thyroid transcription factor-1 (TTF-1) positive, with an epidermal growth factor receptor (EGFR) exon 20 insertion and 5% of tumor cells expressing programed death-ligand 1 (PD-L1).
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
Oral propranolol 10mg tid to treat amivantamab induced scalp ulcers in #EGFR NSCLC @LungCaJournal. Possible mechanisms: vasoconstriction, reducing VEGF and bFGF, promoting apoptosis of endothelial cells, hemangioma-derived stem cells, and pericytes. https://t.co/NfmKpGKBoL
-
-
Mashup Score: 60
The PRIMALung EORTC-1901 trial investigates brain MRI ± PCI in all-stages of SCLC, aiming for non-inferior survival, improve cognition in the era of immunotherapy.@finn_corinne
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet-
PRIMALung (EORTC 1901) compares brain MRI surveillance to prophylactic cranial irradiation (PCI) in patients with #SCLC. Trials in progress section of @LungCaJournal is a nice addition - allows us to know what to watch for (and nice schema figures). https://t.co/Q9Mh6Dy51v
-
Analysis of ctDNA in #HER2 NSCLC receiving pyrotinib and apatinib (PATHER2 study) @LungCaJournal. Clearance of ctDNA associated with longer PFS and OS trend. At resistance, chromatin remodeling pathway genes often mutated, on-target resistance uncommon. https://t.co/KSaBPwJSZF